Funding for this research was provided by:
Japan Agency for Medical Research and Development (16ek0410016h0003)
Grant-In-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (22249025, 16K09928, 15K08790)
The Ministry of Health, Labor, and Welfare of Japan (H26-008)
Received: 19 June 2018
Accepted: 28 September 2018
First Online: 26 October 2018
Ethics approval and consent to participate
: Ethical approval was obtained from the University of Occupational and Environmental Health, Japan Ethics Committee. This retrospective study was approved by the institutional review board, and the requirement to obtain informed consent was waived.
: Not applicable.
: Kei Sakata is an employee of Mitsubishi Tanabe Pharma. Shingo Nakayamada has received speaking fees from Bristol-Myers, Sanofi, AbbVie, Eisai, Eli Lilly, Chugai, Pfizer, Takeda (less than US $10,000 each), and research grants from Mitsubishi-Tanabe, Novartis and MSD. Dr Tanaka has received consulting fees, speaking fees, and/or honoraria from Mitsubishi Tanabe Pharma, Eisai, Pfizer, Abbott Immunology, Janssen, Takeda Industrial Pharma, Santen, AstraZeneca, Astellas, Asahi Kasei, UCB, and GlaxoSmithKline (less than US $10,000 each) and from AbbVie and Chugai (more than US $10,000 each) and research grants from Bristol-Myers Squibb, Mitsubishi Tanabe, MSD, Takeda Industrial Pharma, Astellas, Eisai, Chugai, Pfizer, and Daiichi-Sankyo. All other authors declare no conflict of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.